Novartis AG (NVS)
158.02
-0.84
(-0.53%)
USD |
NYSE |
Aug 24, 16:00
158.00
-0.02
(-0.01%)
After-Hours: 20:00
Novartis Debt to Equity Ratio : 1.180 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.180 |
| March 31, 2026 | 1.220 |
| December 31, 2025 | 0.7669 |
| September 30, 2025 | 0.7224 |
| June 30, 2025 | 0.7773 |
| March 31, 2025 | 0.815 |
| December 31, 2024 | 0.7097 |
| September 30, 2024 | 0.7424 |
| June 30, 2024 | 0.6946 |
| March 31, 2024 | 0.6877 |
| December 31, 2023 | 0.5646 |
| September 30, 2023 | 0.66 |
| June 30, 2023 | 0.5466 |
| March 31, 2023 | 0.561 |
| December 31, 2022 | 0.4703 |
| September 30, 2022 | 0.4692 |
| June 30, 2022 | 0.494 |
| March 31, 2022 | 0.5093 |
| December 31, 2021 | 0.4586 |
| September 30, 2021 | 0.6047 |
| June 30, 2021 | 0.6633 |
| March 31, 2021 | 0.749 |
| December 31, 2020 | 0.6688 |
| September 30, 2020 | 0.7007 |
| June 30, 2020 | 0.6464 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.7209 |
| December 31, 2019 | 0.5254 |
| September 30, 2019 | 0.5734 |
| June 30, 2019 | 0.5886 |
| March 31, 2019 | 0.6477 |
| December 31, 2018 | 0.4082 |
| September 30, 2018 | 0.4078 |
| June 30, 2018 | 0.4212 |
| March 31, 2018 | 0.4798 |
| December 31, 2017 | 0.3833 |
| September 30, 2017 | 0.4171 |
| June 30, 2017 | 0.4371 |
| March 31, 2017 | 0.4625 |
| December 31, 2016 | 0.3181 |
| September 30, 2016 | 0.3543 |
| June 30, 2016 | 0.3639 |
| March 31, 2016 | 0.3912 |
| December 31, 2015 | 0.2846 |
| September 30, 2015 | 0.2959 |
| June 30, 2015 | 0.2955 |
| March 31, 2015 | 0.3288 |
| December 31, 2014 | 0.2884 |
| September 30, 2014 | 0.2748 |
| June 30, 2014 | 0.2903 |
| March 31, 2014 | 0.3021 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Roche Holding AG | -- |
| AstraZeneca PLC | 0.7166 |
| Johnson & Johnson | 0.5771 |
| Eli Lilly & Co. | 1.621 |
| Merck & Co., Inc. | 1.286 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 122.03B |
| Total Liabilities (Quarterly) | 80.09B |
| Shareholders Equity (Quarterly) | 41.54B |
| Current Ratio | 0.8615 |
| Net Debt Paydown Yield | -1.24% |